Monthly Archives: March 2011

Topamax® Warning Label to be Strengthened

The anti-seizure medication Topamax┬« (topiramate) will receive a stronger warning to reflect the newly discovered birth defect risk, according to the U.S. Food and Drug Administration (FDA). The label change follows data that links the medication to the development of … Continue reading

Topamax® Linked to Birth Defects

The U.S. Food and Drug Administration (FDA) informed the public that new data has shown a link between the epilepsy drug topiramate (brand name: Topamax┬«) and certain facial malformations. Infants whose mothers take the drug during the first trimester are … Continue reading